Company: WHWK
Filing Date: 2025-03-31
Form Type: S-3
Source: 0001193125-25-068942
Chunk: 12

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-03-31
Form: S-3
Chunk 12
---
 or any other product candidates we may develop in the future, and any related restrictions, limitations or warnings in the label of an approved product candidate; |

| • |     | the timing, progress and results of preclinical studies and clinical trials for our programs and product                                                                                                                                 
 candidates (including our anticipated timing of submitting three investigational new drug (“IND”) applications for the ADC Therapies with the U.S. Food and Drug Administration in the coming 12 to 24 months), the timing of initiation 
 and completion of studies or trials and related preparatory work, the period during which the results of the trials will become available and our research and development programs;                                                     |

| • |     | the anticipated timing of releasing data for current or future clinical trials; |

| • |     | the anticipated timing of commencement, enrollment, and completion of any current or future clinical trials for 
 the ADC Therapies or any other product candidates we may develop;                                               |

| • |     | our belief that, with the three ADC Therapies, we have the ability to pursue multiple cancer indications with                                                     
 high potential in large addressable patient populations, including and beyond those indications currently expected to be targeted in the upcoming Phase 1 trials; |

| • |     | our belief that the ADC Therapies will be able to target cancers expressing specified tumor markers precisely and 
 deliver the potent, cytotoxic Topoisomerase I (TOPO1) inhibitor at the site of cancer;                            |

| • |     | our view that we are positioned to unlock the high potential of the ADC Therapies due to our track record of                                                                            
 strong execution of novel drug formulation, research, clinical development, and commercialization in oncology, combined with our deep understanding of antibody drug conjugates (ADCs); |

| • |     | our belief that our team is well positioned to execute on our strategy to develop and, if approved, commercialize 
 the ADC Therapies and future pipeline assets to ultimately bring broad benefit to cancer patients worldwide;      |

| • |     | our manufacturing capabilities and strategy; |

| • |     | the expectations regarding the beneficial characteristics, safety, efficacy and therapeutic effects of the ADC 
 Therapies and any other product candidates that we may develop;                                                |

| • |     | the implementation of our business model and our strategic plans for our business; |

6

| • |     | our ability to contract with and rely on third parties to assist in conducting our clinical trials and 
 manufacturing the